News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News Autolus closes on EU okay for leukaemia cell therapy The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.
News Italfarmaco closes on EU okay for Duchenne drug Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).
News Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.
News EMA panel endorses AI for MASH clinical trials PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
News AbbVie closes on Rinvoq approval in inflamed artery disease AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face